Market Place
Sourcing Support
US FDA approves Syndax`s blood cancer drug
16 Nov 2024 //
REUTERS
Syndax Publishes AUGMENT-101 Trial Data On Revumenib In Leukemia
12 Aug 2024 //
PR NEWSWIRE
Syndax Announces PDUFA Date Extension For Revumenib In Acute Leukemia
29 Jul 2024 //
PR NEWSWIRE
Syndax Presents Updated Revumenib Data At EHA 2024
14 Jun 2024 //
PR NEWSWIRE
Syndax Plans Phase 1b Trial Of Revumenib In Relapsed/Refractory MSS CRC
06 Jun 2024 //
PR NEWSWIRE
Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial
08 Apr 2024 //
PR NEWSWIRE
Syndax FDA Priority Review of NDA for Revumenib Relapsed/Refractory KMT2Ar
26 Mar 2024 //
PR NEWSWIRE
Syndax Presents Data from AUGMENT-101 Trial of Revumenib in Acute Leukemia
12 Dec 2023 //
PR NEWSWIRE
City of Hope presents pivotal clinical trial data at ASH conference on revumenib
12 Dec 2023 //
BUSINESSWIRE
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias
11 Dec 2023 //
PRESS RELEASE
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data
04 Dec 2023 //
PR NEWSWIRE
Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib
21 Nov 2023 //
PR NEWSWIRE
Syndax Announces Data Supporting Impressive Clinical Profile of Revumenib
02 Nov 2023 //
PR NEWSWIRE
Syndax to Initiate NDA Submission of Revumenib in KMT2Ar Acute Leukemia
24 Oct 2023 //
PR NEWSWIRE
Syndax Announces Trial of Revumenib in Relapsed/Refractory KMT2Ar Meets Endpoint
02 Oct 2023 //
PRESS RELEASE
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib
29 Sep 2023 //
PR NEWSWIRE
Novel small molecule drug facilitates leukaemia remission
15 Mar 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.